Nanoscope Therapeutics is a BLA-Filing stage company developing sight-restoring mutation-agnostic gene therapies for patients suffering from inherited retinal diseases and geographic atrophy due to Age-related Macular Degeneration (AMD).

Nanoscope anticipates a near-term FDA approval of a first-in-class/best-in-class therapy to treat all forms of advanced RP, representing tens of thousands of patients at launch with premium pricing. The FDA has granted Nanoscope's request for a rolling BLA submission for this program, and modules are presently being staged for the submission.

A similar commercial opportunity exists for a follow-on Ph3-ready asset for tens of thousands of patients with Stargardt Macular degeneration.

Nanoscope's proprietary MCO optogenetic therapeutic platform has mutation-agnostic and disease-agnostic potential across inherited retinal dystrophies. Next-generation MCO assets targeting AMD-related geographic atrophy are IND-ready